HomeCompareSKLYF vs ABBV

SKLYF vs ABBV: Dividend Comparison 2026

SKLYF yields 1.18% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 SKLYF wins by $1.78M in total portfolio value· pulled ahead in Year 6
10 years
SKLYF
SKLYF
● Live price
1.18%
Share price
$10.70
Annual div
$0.13
5Y div CAGR
89%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1.89M
Annual income
$1,467,059.02
Full SKLYF calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — SKLYF vs ABBV

📍 SKLYF pulled ahead of the other in Year 6

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSKLYFABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SKLYF + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SKLYF pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SKLYF
Annual income on $10K today (after 15% tax)
$100.66/yr
After 10yr DRIP, annual income (after tax)
$1,247,000.17/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, SKLYF beats the other by $1,225,944.16/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SKLYF + ABBV for your $10,000?

SKLYF: 50%ABBV: 50%
100% ABBV50/50100% SKLYF
Portfolio after 10yr
$994.2K
Annual income
$745,915.39/yr
Blended yield
75.03%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

SKLYF
No analyst data
Altman Z
2.0
Piotroski
7/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SKLYF buys
0
ABBV buys
0
No recent congressional trades found for SKLYF or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSKLYFABBV
Forward yield1.18%3.06%
Annual dividend / share$0.13$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR89%40.6%
Portfolio after 10y$1.89M$102.3K
Annual income after 10y$1,467,059.02$24,771.77
Total dividends collected$1.83M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: SKLYF vs ABBV ($10,000, DRIP)

YearSKLYF PortfolioSKLYF Income/yrABBV PortfolioABBV Income/yrGap
1$10,924$223.81$11,550$430.00$626.00ABBV
2$12,120$431.86$13,472$627.96$1.4KABBV
3$13,815$846.37$15,906$926.08$2.1KABBV
4$16,486$1,704.03$19,071$1,382.55$2.6KABBV
5$21,232$3,591.88$23,302$2,095.81$2.1KABBV
6← crossover$30,889$8,170.96$29,150$3,237.93+$1.7KSKLYF
7$54,049$20,997.42$37,536$5,121.41+$16.5KSKLYF
8$122,729$64,896.75$50,079$8,338.38+$72.7KSKLYF
9$391,612$260,292.14$69,753$14,065.80+$321.9KSKLYF
10$1,886,084$1,467,059.02$102,337$24,771.77+$1.78MSKLYF

SKLYF vs ABBV: Complete Analysis 2026

SKLYFStock

Skylark Holdings Co., Ltd. operates restaurants in Japan and internationally. The company also engages in the provision of food services; and related businesses. It operates Western, Chinese, Japanese, Sushi, and Italian restaurants primarily under the Gusto, Bamiyan, Jonathan´s, Syabu-Yo, Yumean, Steak Gusto, Karayoshi, Grazie Gardens, Aiya, Musashino Mori Coffee, S Gusto, Totoyamichi, chawan, Tonkaratei, La Ohana, Yumean Shokudo, GRAND BUFFET, Miwami, Kushi-Yo, Tomato and Onion, Jyu-Jyu Karubi, and FLO PRESTIGE brand names. The company also provides foodstuffs and concession stand products delivery, store cleaning and maintenance, and linen supply services. As of June 30, 2022, it operated 3,085 stores. The company was formerly known as Skylark Co., Ltd. and changed its name to Skylark Holdings Co., Ltd. in July 2018. Skylark Holdings Co., Ltd. was founded in 1962 and is based in Musashino, Japan.

Full SKLYF Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this SKLYF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SKLYF vs SCHDSKLYF vs JEPISKLYF vs OSKLYF vs KOSKLYF vs MAINSKLYF vs JNJSKLYF vs MRKSKLYF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.